Sebastian Amigorena

Sebastian Amigorena is a CNRS Research Director and Research Team Leader at Institut Curie, Paris, heading the Immune Responses and Cancer team (Unit: Immunity and Cancer, U932). His career spans fundamental immunology, cell biology, and translational cancer research.

• PhD in Paris (1990)
• Postdoctoral fellowship at Yale University
• Founded INSERM AVENIR group (1995)

Research Focus: Interdisciplinary work at immunology-cell biology interfaces, pioneering antigen presentation and cross-presentation mechanisms in dendritic cells, T cell exhaustion dynamics, and transposable elements' role in anti-tumor immunity. His team uses cutting-edge approaches like RNAseq, ChIP-Seq, intravital microscopy, and mouse models.

Publication Trends: Recent work emphasizes transposable elements, tumor immunity, and epigenetic regulation of T cell memory and exhaustion. Earlier studies established foundational knowledge in IgG receptor functions and dendritic cell phagocytosis.

Scientific Recognition:

• 2025: Franco-Brazilian chair for CellAction's cell therapy platform
• 2021: Two RHU program awards for innovative cancer research

Collaborations & Grants: Key partnerships with Mnemo Therapeutics (75M€ spin-off funding), CellAction platform, and CNRS. His team includes permanent researchers, engineers, and PhD student Darawan Tabtim-on.

Laboratory: Investigates dendritic cell membrane transport, chromatin organization in T cell differentiation, and transposable elements' impact on tumor immunity. Technologies span proteogenomics, single-cell RNA-seq, and in vivo CRISPR screens.